FDA grants fast track designation to CERC-002 for treatment of hospitalised patients with covid-19

This human anti-LIGHT or tumour necrosis factor superfamily member 14 monoclonal antibody is considered to have potential to treat a number of LIGHT-associated immune diseases including cytokine storm-induced COVID-19 acute respiratory syndrome

Source:

Biospace Inc.